Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Strong Trading Volume – Here’s Why

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw unusually-strong trading volume on Wednesday . Approximately 302,588 shares were traded during mid-day trading, an increase of 58% from the previous session’s volume of 191,400 shares.The stock last traded at $26.25 and had previously closed at $26.80.

Chugai Pharmaceutical Stock Performance

The firm has a market capitalization of $86.22 billion, a P/E ratio of 32.75 and a beta of 0.63. The business has a 50 day simple moving average of $24.95 and a two-hundred day simple moving average of $24.09.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Friday, October 24th. The company reported $0.23 earnings per share (EPS) for the quarter. The firm had revenue of $2.26 billion during the quarter. Chugai Pharmaceutical had a return on equity of 20.63% and a net margin of 32.74%. On average, equities analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.